RCM
PYXS icon

Radcliffe Capital Management’s Pyxis Oncology PYXS Stock Holding History

Radcliffe Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-53,288
Closed – – 228
2023
Q3 		$0 Buy
+53,288
New +$123K ﹤0.01% 484

Other funds holding PYXS

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Radcliffe Capital Management's PYXS Position: Q4 2023 in Review

Radcliffe Capital Management sold out of Pyxis Oncology (PYXS) in Q4 2023, closing a stake of 53,288 shares.

Radcliffe Capital Management first reported a position in PYXS in Q3 2023 and held it in 1 quarter. The position peaked at $0 in Q3 2023. 51 funds tracked by Wall St. Rank hold PYXS as of Q4 2023.

  • Radcliffe Capital Management reported no remaining Pyxis Oncology position as of Q4 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 53,288 Pyxis Oncology shares in Q4 2023.
  • Radcliffe Capital Management first reported a position in Pyxis Oncology in Q3 2023 and held it in 1 quarter.
  • Radcliffe Capital Management's Pyxis Oncology position peaked at $0 in Q3 2023.
  • 51 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2023.

Based on Radcliffe Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.